Mechanism

glucose lowering for cardiovascular prevention

treatment

comparator

All cause death (0)

All cause death (1)

Coronary event (2)

Amputations (3)

Cardiovascular death (4)

Death from cancer (5)

Fatal MI (6)

Heart failure (7)

Long term death (8)

Fatal stroke (9)

Non fatal stroke (10)

Non fatal MI (11)

stroke (fatal and non fatal) (12)

myocardial infarction (fatal and non fatal) (13)

hospitalisation for heart failure (14)

cardiovascular events (15)

cardiovascular events (16)

cardiac event (fatal and non fatal ) (17)

A CHANGER (18)

vomiting (19)

diarrhoea (20)

Adverse events leading to treatment discontinuation (21)

non cardiovascular death (22)

macrovascular events (23)

microvascular events (24)

nephropathy (25)

retinopathy (26)

macrovascular or microvascular events (27)

fatal HF (28)

Peripheral vascular events (29)

all cause death, MI, stroke (30)

change in HbA1c (%) (31)

change in body weight (kg) (32)

long term cardiovascular events (33)

vision loss (34)

severe hypoglycemia (35)

HbA1c (36)

all hypoglycemia (37)

HbA1c < 6.5% (38)

HbA1c <7% (39)

treatment-emergent adverse events (TEAEs) (40)

serious adverse events (41)

severe adverse events (42)

change in daily mean glucose, mmol/L (43)

change in FSG, mmol/L (44)

Edit

Alogliptin

diabetes type 2, in all type of patients

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Linagliptin

diabetes type 2, in all type of patients

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Saxagliptin

diabetes type 2, in all type of patients

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Sitagliptin

diabetes type 2, in all type of patients

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Exenatide

diabetes type 2, in all type of patients

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Liraglutide

diabetes type 2, in all type of patients

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Lixisenatide

diabetes type 2, in all type of patients

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Semaglutide

diabetes type 2, in all type of patients

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Glargine

diabetes type 2, in all type of patients

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Aleglitazar

diabetes type 2, in all type of patients

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Canagliflozin

diabetes type 2, in all type of patients

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Dapagliflozin

diabetes type 2, in all type of patients

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Empagliflozin

diabetes type 2, in all type of patients

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Pioglitazone

diabetes type 2, in all type of patients

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-